Malloy Kirk 4
4 · RAPID MICRO BIOSYSTEMS, INC. · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
Rapid Micro (RPID) Director Malloy Kirk Acquires 12,787 Shares & Warrants
What Happened
Malloy Kirk, a director of Rapid Micro Biosystems (RPID), participated in a registered direct offering on May 29, 2026 and acquired 12,787 shares of Class A common stock for approximately $1.96 per share (total reported $24,999). At the same time he received accompanying Series A and Series B warrants (each covering 12,787 shares or pre-funded warrants in lieu) issued in connection with the same purchase. The filing lists these as grant/acquisition transactions (code A); this is a purchase/acquisition rather than a sale.
Key Details
- Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (filed within the standard 2-business-day reporting window).
- Price: filing shows $1.96 per share (total $24,999); footnote states the purchase price was $1.955 per share for each share and accompanying warrants.
- Securities received: 12,787 shares + Series A and Series B warrants covering 12,787 shares each (or pre-funded warrants in lieu). Two warrant entries are reported as derivative acquisitions at $0.00 (reflecting issuance accompanying the share purchase).
- Shares owned after transaction: Not specified in the provided Form 4 excerpt.
- Footnotes of note: (F1) purchase was via a registered direct offering and approved by the company’s compensation committee under Rule 16b-3; (F2) some shares are held in a family trust where the reporting person shares investment power and family members are beneficiaries; (F3) the Series A/B warrants include an exercise limitation — they cannot be exercised if the resulting beneficial ownership would exceed 4.99% of outstanding Class A shares.
Context
This was an outright purchase/accompanying-warrant issuance (not an option exercise or sale). Purchases by directors can be interpreted by some investors as alignment with the company, but filings are factual records of transactions and do not state motives. The warrants and their 4.99% ownership cap are important for understanding dilution and exercise constraints.
Insider Transaction Report
- Award
Class A Common Stock
[F1]2026-05-29$1.96/sh+12,787$24,999→ 60,687 total - Award
Series A Warrant (right to buy)
[F1][F3]2026-05-29+12,787→ 12,787 totalExercise: $1.96From: 2026-11-29Exp: 2027-05-29→ Class A Common Stock (12,787 underlying) - Award
Series B Warrant (right to buy)
[F1][F3]2026-05-29+12,787→ 12,787 totalExercise: $2.34From: 2026-11-29Exp: 2031-05-29→ Class A Common Stock (12,787 underlying)
- 10,000(indirect: By Trust)
Class A Common Stock
[F2]
Footnotes (3)
- [F1]On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
- [F2]Shares held in family trust as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- [F3]The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.